Skip to main content
. 2024 Aug 29;16(9):1144. doi: 10.3390/pharmaceutics16091144

Table 1.

ARRIVE analysis.

Authors and Year Arrive Item Total
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Alam et al. (2018) [25] 2 1 1 0 0 2 2 2 2 2 0 1 2 2 1 0 1 1 0 0 2 24
Alshammari et al. (2019) [43] 2 1 1 0 0 2 2 2 2 2 1 2 2 2 2 0 1 1 0 2 2 29
Ampuero et al. (2015) [29] 2 1 1 0 1 2 2 2 2 2 1 2 2 2 1 1 1 1 0 0 2 28
Bah et al. (2011) [31] 2 1 1 0 2 2 2 2 2 0 1 2 2 2 1 0 1 1 0 0 1 25
Berton et al. (1999) [47] 2 1 1 0 1 2 2 2 2 2 1 2 2 1 2 1 1 1 0 0 0 26
Dashti et al. (2022) [27] 2 1 1 0 0 2 2 2 2 2 1 2 2 2 1 1 1 2 0 2 2 30
Desbonet et al. (2010) [44] 2 1 1 0 1 2 2 2 2 2 1 2 2 2 2 1 1 1 0 2 0 29
Evans et al. (2012) [26] 2 1 1 0 1 2 2 2 2 1 1 2 1 2 2 1 1 1 0 2 2 29
Guo et al. (2009) [28] 2 1 1 0 2 2 2 2 2 2 1 2 2 1 2 0 1 1 0 0 0 26
Hale et al. (2017) [32] 2 1 1 0 1 2 2 2 2 0 2 2 2 2 2 1 1 1 0 0 2 28
Jagadeesan et al. (2019) [41] 2 1 1 0 0 2 2 2 2 2 2 2 2 2 2 1 1 1 0 2 2 31
Khedr et al. (2015) [35] 2 1 1 0 0 2 0 2 2 2 2 2 2 1 2 0 1 1 0 0 2 25
Khedr et al. (2018) [30] 2 1 1 0 0 2 2 2 2 2 1 1 1 1 0 0 1 1 0 2 2 24
Lin et al. (2014) [33] 2 1 1 0 0 2 2 2 2 0 1 2 2 2 1 0 1 1 0 1 2 25
Marchetti et al. (2020) [34] 2 1 1 0 1 2 1 2 2 0 1 2 2 1 1 0 1 1 0 2 2 25
Qi et al. (2018) [36] 2 1 1 0 0 2 2 2 2 2 1 2 2 1 2 0 1 1 0 0 2 26
Ratajczak et al. (2019) [46] 2 1 1 0 0 2 2 2 2 2 1 2 2 1 2 1 1 1 0 0 0 25
Solak et al. (2022) [37] 2 1 1 0 0 2 2 2 2 2 2 2 2 2 2 1 1 1 0 2 2 31
Steyn et al. (2018) [48] 1 1 1 0 1 2 2 2 2 2 2 1 2 2 1 1 1 1 0 0 2 27
Szymańska et al. (2009) [45] 2 1 1 1 0 2 1 2 2 2 1 2 2 1 2 0 1 1 0 0 2 26
Zavvari et al. (2020) [39] 2 0 1 0 0 2 2 2 2 2 1 2 2 2 1 1 1 1 0 0 2 26
Zaavari et al. (2020) [38] 2 1 1 0 0 2 2 2 2 2 1 2 2 2 1 0 1 1 0 0 2 26
Zangen et al. (2001) [49] 1 1 1 0 0 2 1 2 2 2 1 2 1 1 1 0 1 1 0 0 0 20
Zhao et al. (2008) [42] 2 0 1 1 1 2 2 2 2 2 1 2 2 1 2 0 1 1 0 0 0 25
Zhou et al. (2021) [40] 2 1 1 0 1 2 2 2 2 2 1 2 2 1 1 1 1 1 0 2 2 29
Category score 48 23 25 2 13 50 45 50 50 41 29 47 47 39 37 12 25 26 0 19 37 665
Maximum score 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 50 1050
Ratio 0.96 0.46 0.50 0.04 0.26 1.00 0.90 1.00 1.00 0.82 0.58 0.94 0.94 0.78 0.74 0.24 0.50 0.52 0.00 0.38 0.74 0.63

ARRIVE items: 1. Study design, 2. Sample size, 3. Inclusion and exclusion criteria, 4. Randomisation, 5. Blinding, 6. Outcome measures, 7. Statistical methods, 8. Experimental animals, 9. Experimental procedures, 10. Results, 11. Abstract, 12. Background, 13. Objectives, 14. Ethical statement, 15. Housing and husbandry, 16. Animal care and monitoring, 17. Interpretation/scientific implications, 18. Generalisability/translation, 19. Protocol registration, 20. Data access, 21. Declaration of interest.